Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Expansion of the SARS-CoV-2 BA. 4 and BA. 5 Omicron subvariants in populations with
prevalent immunity from prior infection and vaccination, and associated burden of severe …

The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …

The development of neutralizing antibodies (nAbs) is an important strategy to tackle the
Omicron variant. Omicron N-terminal domain (NTD) mutations including A67V, G142D, and …

In this Review, we have addressed some recent developments in the discovery and
applications of anti-human immunodeficiency virus type− 1 (HIV− 1) broadly neutralizing …

Since November 2021, Omicron has been the dominant severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) variant that causes the coronavirus disease 2019 (COVID-19) …

Introduction The COVID-19 pandemic is a major global public health crisis. More than 2
years into the pandemic, effective therapeutic options remain limited due to rapid viral …

Seven coronaviruses are known to cause infection/disease in humans. Of these, human
coronavirus (HCoV)-229E and HCoV-NL63 are alphacoronaviruses (α-CoVs), whereas …

The continuous emergence of SARS-CoV-2 variants, particularly the newly circulating
Omicron XBB subvariants, has led to a significant reduction in the neutralizing potency and …